Volume : 09, Issue : 09, September – 2022

Title:

33.COMPREHENSIVE REVIEW ON COATED PELLETS
‬

Authors :

Aditya Vinayak Dubewar, Prof.V.J.Masirkar

Abstract :

Multiple unit-controlled release dosage forms offer various advantages over their single unit counterparts. Most of these advantages are associated with the uniform distribution of multiparticulates throughout the gastrointestinal tract. Though coated pellets can be filled into hard gelatin capsules, tablet formulation is the preferred one because of various advantages associated with it. However, compression of coated pellets is a challenging task necessitating the optimization of various formulation and process variables. The key formulation variables include composition, porosity, size, shape and density of the pellets; type and amount of polymer coating; nature, size and amount of tableting excipients. The pellet core should be strong with some degree of plasticity. It should be highly porous, small, with an irregular shape. The critical density to achieve prolonged release was reported to lie between 2.4 and 2.8 g/cm3. Acrylic polymer films are more flexible and more suitable for the coating of pellets to be compressed into tablets. Thicker coatings offer better resistance to frictional forces. Solvent based coatings are more flexible and have a higher degree of mechanical
stability than the aqueous based ones. The tableting excipients should have cushioning property. They should not be significantly different in size and density from those of the pellet cores in order to avoid segregation. Addition of 30%-60% of tableting excipients is necessary to avoid any damage to the polymer coat and to retain its functional property.

Cite This Article:

Please cite this article in Aditya Vinayak Dubewar et al, Comprehensive Review On Coated Pellets., Indo Am. J. P. Sci, 2022; 09(9).

Number of Downloads : 10

References:

1. Ghebre-Selassie, I. Pellets: A General Overview. In Pharmaceutical Pelletization Technology; Ghebre-Selassie, I., Ed.; Drugs and the Pharmaceutical Sciences; Marcel Dekker Inc.: New York, NY, USA, 1989; Volume 37, pp. 1–13.
2. Kállai, N.; Antal, I. Importance and pharmaceutical technological considerations of neutral pellets. Acta Pharm. Hung. 2006, 76, 208–212. [PubMed]
3. Bruschi, M.L. Modification of Drug Release. In Strategies to Modify the Drug Release from Pharmaceutical System; Bruschi, M.L., Ed.; Woodhead Publishing: Sawston, UK, 2015; pp. 15–28.
4. Yun, Y.H.; Lee, B.K.; Park, K. Controlled Drug Delivery: Historical perspective for the next generation. J. Control. Release 2015, 219, 2–7. [CrossRef] [PubMed]
5. GlaxoSmithKline DX: L58 Prescribing Information—Dexedrine® Spansule® Sustained-Release Capsules and Tablets; GlaxoSmithKline: Brentford, UK, 2007.
6. Highlights of Prescribing Information: RIOMET ER (Metformin Hydrochloride for Extended-Release Oral Suspension Sun Pharmaceutical Industries Limited). Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212595s0 00lbl.pdf (accessed on 10 January 2022).
7. Venkatesh, G.M.; Stevens, P.J.; Lai, J.-W. Development of orally disintegrating tablets comprising controlled-release multiparticu- late beads. Drug Dev. Ind. Pharm. 2012, 38, 1428–1440. [CrossRef] [PubMed]
8. Antra MUPS 20 mg|Zusammensetzung|Arzneimitteldatenbank | Aponet.De. Available online: https://www.aponet.de/ service/arzneimitteldatenbank/arzneimittel/anwendungsdetails/zusammensetzung/3339612921/Omeprazol (accessed on 11 January 2022).
9. Krämer, J.; Blume, H. Biopharmaceutical Aspects of Multiparticulates. In Multipaticulate Oral Drug Delivery; Ghebre-Sellassie, I.,
10. Ed.; CRC Press: Boca Raton, FL, USA, 1994; pp. 307–332.
11. Tang, E.S.K.; Chan, L.W.; Heng, P.W.S. Coating of Multiparticulates for Sustained Release. Am. J. Drug Deliv. 2005, 3, 17–28. [CrossRef]
12. Podczeck, F., Newton, J.M., 1994. A shape factor to characterize the quality of spheroids. J. Pharm. Pharmacol. 46, 82–85.
13. Podczeck, F., Rahman, S.R., Newton, J.M., 1999. Evaluation of a standardised procedure to assess the shape of pellets using image analysis. Int. J. Pharm. 192, 123

14. Tomer, G., Podczeck, F., Newton, J.M., 2001. Extrusion/ spheronization of a group of chemically similar drug models: I. Extrusion parameters. Int. J. Pharm. 217, 237–248.
15. Marijima, T., McGinity, J. B., pharm. Dev. Technol., 2000, 116,211-221.
16. Woodruff, C. W., Nuselle, N. O., J. Pharm. Sci.,1972,61,787-790.
17. Gandhi, R., Kaul, C.L., Panchagnula, R., Pharm. Sci.Tech.Today, 1999, 2(4), 160–81.
18. Otsuka, M., Gao, J., Mastusuda, Y., Drug. Dev. Ind. Pharm., 1994, 20, 2977-2992.
19. Sherrington, P. J., Oliver, R., In; Goldberg, A. S. (ed.), Granulation, Heyden, London, Philadelphia, 1981, pp. 141-152.
20. Holt RI, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 4th ed. UK: Wiley-Back Well; 2010.
21. Patel SA, Patel NG, Joshi AB. Multiple unit pellet system (MUPS) based fast disintegrating delayed-release tablets for pantoprazole delivery. Int J Pharm Pharm Sci 2018;10:138-44.
22. Jain K. Gastro Retentive Drug Delivery: Progress in Controlled and Novel Drug Delivery System. 1st ed. New Delhi: CBS Publisher and Distributer; 2004. p. 82- 90.
23. Asian Edition. The United State Pharmacopeia. New York: Asian Edition; 2000. p. 2059.
24. Grass GM., Robinson JR, Dekker M. In: Banker GS, Rhodes CT, editors. Modern Pharmaceutics. New York: Informa Healthcare USA Inc.; 1996. p. 635.
25. Ali M. Textbook of Pharmacognosy. 2nd ed. New Delhi: CBS Publishers and Distributors; 2012. p. 71-90.
26. Kokate C, Purohit A, Gokhle S. Pharmacognosy. 42nd ed. Pune: Nirali Prakashan; 2008.
27. Begum R, Aleemudin M, Gautam T. Effect of natural gums on oral sustained release matrix tablets of chloroxone. Int Res J Pharm 2012;3:426-7.
28. Rao NR, Yadav A. Formultion and evaluation of zero order release glipizide bilayer matrix tablet using natural and synthetic polymers. Int J Curr Pharm Res 2010;2:34-42.
29. Kumar AA. Formulation and evaluation of sustained release valsatran matrix tablets by using natural polymers. Int J Pharm Chem Biol Sci 2012;2:14